Patents Assigned to FRED HUTCHINSON CANCER CENTER
-
Publication number: 20230151094Abstract: Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.Type: ApplicationFiled: March 31, 2021Publication date: May 18, 2023Applicant: Fred Hutchinson Cancer CenterInventors: Cameron J. Turtle, Roland B. Walter, George S. Laszlo, Salvatore Fiorenza
-
Patent number: 11648290Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: GrantFiled: June 21, 2021Date of Patent: May 16, 2023Assignees: FRED HUTCHINSON CANCER CENTER, BLAZE BIOSCIENCE, INC.Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
-
Publication number: 20230144405Abstract: A suite of novel human anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33 or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).Type: ApplicationFiled: March 31, 2021Publication date: May 11, 2023Applicant: Fred Hutchinson Cancer CenterInventors: Roland B. Walter, George S. Laszlo
-
Publication number: 20230133243Abstract: The present disclosure provides, among other things, immune suppression regimens for in vivo gene therapy and uses thereof. In various embodiments of the present disclosure, in vivo gene therapy includes delivery of at least one exogenous coding nucleic acid sequence to a stem cell of the subject. Success of in vivo gene therapy can be inhibited or reduced by immunotoxicity. The present disclosure provides compositions and methods, including among other things immune suppression regimens, that reduce immunotoxicity of in vivo gene therapy, e.g., in vivo gene therapy including administration of a viral gene therapy vector to a subject.Type: ApplicationFiled: April 12, 2021Publication date: May 4, 2023Applicants: Fred Hutchinson Cancer Center, University of WashingtonInventors: Andre Lieber, Hans-Peter Kiem
-
Publication number: 20230103618Abstract: In some aspects, the disclosure provides antibody-based reagents that specifically bind a tropomyosin receptor kinase B (TrkB) isoform that is associated with cancers. In some embodiments, the isoform is TrkB.T1. In some embodiments, the antibody or antibody derivative specifically binds a polypeptide comprising, consisting essentially of, or consisting of the sequence FVLFHKIPLDG (SEQ ID NO:1), or a sequence with at least 80% sequence identity thereto. In other aspects, the disclosure provides methods of producing the antibody or antibody derivative, related hybridomas, and methods of detecting and treating cancers incorporating use of the disclosed antibody reagents.Type: ApplicationFiled: January 29, 2021Publication date: April 6, 2023Applicant: Fred Hutchinson Cancer CenterInventors: Eric Holland, Siobhan Pattwell
-
Patent number: 11603544Abstract: Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.Type: GrantFiled: June 5, 2018Date of Patent: March 14, 2023Assignee: Fred Hutchinson Cancer CenterInventors: Jennifer E. Adair, Reza Shahbazi
-
Patent number: 11578118Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.Type: GrantFiled: October 19, 2018Date of Patent: February 14, 2023Assignee: Fred Hutchinson Cancer CenterInventors: Justin J. Taylor, Howell F. Moffett
-
Patent number: 11566061Abstract: Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.Type: GrantFiled: January 5, 2018Date of Patent: January 31, 2023Assignee: Fred Hutchinson Cancer CenterInventor: Matthias Stephan
-
Patent number: 11548923Abstract: Described herein are peptides and variants and mutants thereof capable of interacting with TEAD, disrupting the HIPPO pathway, or modulating the activity or function of TEAD interactions in a cell. Pharmaceutical compositions and uses of peptides, as well as methods of designing and manufacturing such peptides, to treat cancer, tumor, or any other disease/condition associated with a dysregulated HIPPO pathway or uncontrolled cell growth are also described herein.Type: GrantFiled: January 18, 2018Date of Patent: January 10, 2023Assignee: FRED HUTCHINSON CANCER CENTERInventors: James M. Olson, Zachary Crook, Philip H. Bradley
-
Publication number: 20220411472Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: ApplicationFiled: July 2, 2020Publication date: December 29, 2022Applicant: Fred Hutchinson Cancer CenterInventors: Barry L. Stoddard, Philip Bradley, Colin E. Correnti
-
Patent number: 11534461Abstract: The present disclosure provides binding proteins and TCRs with high affinity and specificity against Merkel cell polyomavirus T antigen epitopes or peptides, T cells expressing such high affinity Merkel cell polyomavirus T antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating Merkel cell carcinoma.Type: GrantFiled: November 14, 2017Date of Patent: December 27, 2022Assignees: FRED HUTCHINSON CANCER CENTER, UNIVERSITY OF WASHINGTONInventors: Aude G. Chapuis, Paul T. Nghiem, Megan S. McAfee, Natalie J. Miller, Kelly Garneski Paulson, David Martin Koelle, Thomas M. Schmitt, Candice Church
-
Publication number: 20220380776Abstract: Systems and methods to selectively protect therapeutic cells by reducing CD33 expression in the therapeutic cells using base editors and targeting non-therapeutic cells with an anti-CD33 therapy are described. The selective protection results in the enrichment of the therapeutic cells while simultaneously targeting any diseased, malignant and/or non-therapeutic CD33 expressing cells within a subject.Type: ApplicationFiled: October 22, 2020Publication date: December 1, 2022Applicants: Fred Hutchinson Cancer Center, University of WashingtonInventors: Olivier Humbert, Hans-Peter Kiem, Roland B. Walter, Andre Lieber, Chang Li
-
Patent number: 11458191Abstract: The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.Type: GrantFiled: December 8, 2021Date of Patent: October 4, 2022Assignee: FRED HUTCHINSON CANCER CENTERInventors: Rachel Perret, Philip D. Greenberg, Thomas M. Schmitt, Aude G. Chapuis, Ingunn M. Stromnes, Tijana Martinov
-
Patent number: 11440945Abstract: Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.Type: GrantFiled: January 5, 2018Date of Patent: September 13, 2022Assignee: Fred Hutchinson Cancer CenterInventor: Matthias Stephan
-
Patent number: 11439667Abstract: The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types.Type: GrantFiled: October 17, 2019Date of Patent: September 13, 2022Assignee: FRED HUTCHINSON CANCER CENTERInventors: Irwin D. Bernstein, Brandon K. Hadland
-
Patent number: 11441180Abstract: The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.Type: GrantFiled: November 6, 2020Date of Patent: September 13, 2022Assignee: Fred Hutchinson Cancer CenterInventor: Jason H. Bielas
-
Patent number: 11397183Abstract: The instant disclosure provides biomarkers and methods for identifying subjects at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. For example, adverse event biomarkers may be measured in a subject before pre-conditioning chemotherapy, before immunotherapy (e.g., adoptive immunotherapy infusion comprising a chimeric antigen receptor (CAR) modified T cell), or shortly after pre-conditioning chemotherapy and/or immunotherapy. Exemplary biomarkers include temperature, cytokine levels and endothelial activation biomarkers, such as angiopoietin 2, von Willebrand factor (vWF), ratio of angiopoietin 2 to angiopoietin 1, and ratio of ADAMTS13 to vWF. Also provided are methods of treating subjects identified as at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both to minimize such potential adverse events.Type: GrantFiled: February 9, 2018Date of Patent: July 26, 2022Assignees: Fred Hutchinson Cancer Center, University of Washington, Bloodworks NorthwestInventors: W. Conrad Liles, Cameron J. Turtle, David G. Maloney, Stanley R. Riddell, Mark M. Wurfel, Jose Lopez, Dominic Chung, Junmei Chen
-
Patent number: 11382954Abstract: The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.Type: GrantFiled: August 20, 2021Date of Patent: July 12, 2022Assignee: FRED HUTCHINSON CANCER CENTERInventors: Rachel Perret, Philip D. Greenberg, Thomas M. Schmitt, Aude G. Chapuis, Ingunn M. Stromnes, Tijana Martinov
-
Patent number: 11359179Abstract: The present disclosure provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, the methods comprising culturing the precursor cells in the presence of a Notch 1 agonist, Notch 2 agonist or Notch 1 agonist and Notch 2 agonist (and, in particular embodiments, one or more growth factors) that support the proliferation but not differentiation of the non-terminally differentiated cells. The present disclosure further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch 1 agonist, Notch 2 agonist or Notch 1 agonist and Notch 2 agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and/or differentiated cells of the disclosure can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs.Type: GrantFiled: December 20, 2018Date of Patent: June 14, 2022Assignee: FRED HUTCHINSON CANCER CENTERInventor: Irwin D. Bernstein